Sartorius Stedim Biotech entered a partnership with Nanotein Technologies involving a $3 million minority investment to commercialize and co-develop products that enhance immune cell manufacturing. Nanotein’s NanoSpark platform includes soluble activators to improve expansion and quality of T cells and natural killer cells, critical for CAR-T and NK cell therapies. The collaboration aims to accelerate innovation and offer streamlined workflow solutions in cell and gene therapy manufacturing.